Residual risk in cardiovascular and renal diseases and the potential role of aldosterone synthase inhibitors - Takeaways - MDSpire

Residual risk in cardiovascular and renal diseases and the potential role of aldosterone synthase inhibitors

  • By

  • Kausik Umanath

  • Jamie P. Dwyer

  • Robert J. Mentz

  • May 29, 2026

  • 0 min

Share

  • 1

    RAAS blockade has been essential in treating cardiovascular and kidney diseases for nearly 30 years.

  • 2

    Residual risk for adverse cardiorenal outcomes remains significant despite various RAAS-targeting therapies.

  • 3

    Aldosterone synthase inhibitors (ASi) may reduce residual risk by decreasing aldosterone production.

  • 4

    Preliminary ASi clinical trials show promise in improving blood pressure control and reducing albuminuria.

  • 5

    Ongoing phase III trials are investigating the therapeutic potential of ASi agents in cardiorenal disease.

Original Source(s)

Residual risk in cardiovascular and renal diseases and the potential role of aldosterone synthase inhibitors

  • by Kausik Umanath, Jamie P. Dwyer, Robert J. Mentz

  • May 29, 2026

Related Content

Role of psychological resilience and psychological distress in linking fear of disease progression to quality of life in chronic heart failure: a cross-sectional serial mediation analysis

Outcomes following coronary artery bypass grafting with temporary left ventricular assist device support

Longitudinal assessment of myocardial involvement in PASC-CVS: a single-center study from China based on multiparametric CMR